Literature DB >> 2310276

Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah.

R R Williams1, P N Hopkins, S C Hunt, L L Wu, S J Hasstedt, J M Lalouel, K O Ash, B M Stults, H Kuida.   

Abstract

The frequency of familial dyslipidemia syndromes was determined from blood tests in 33 objectively ascertained families with early coronary heart disease (CHD) (two or more siblings with CHD by the age of 55 years). Three fourths of persons with early CHD in these families had 90th percentile lipid abnormalities (cholesterol level at or above the 90th percentile, triglyceride level at or above the 90th percentile, and/or high-density lipoprotein cholesterol (HDL-C) level at or less than the 10th percentile). The HDL-C and triglyceride abnormalities were twice as common as low-density lipoprotein-cholesterol abnormalities. The most common syndromes found were familial combined hyperlipidemia (36% to 48% of families with CHD), familial dyslipidemic hypertension (21% to 54% of families with CHD), and isolated low levels of HDL-C (15%), with overlapping familial dyslipidemic hypertension with familial combined hyperlipidemia and low-level HDL-C. Well-defined monogenic syndromes were uncommon: familial hypercholesterolemia being 3% and familial type III hyperlipidemia, 3%. Another 15% of families with CHD had no lipid abnormalities at the 90th percentile. Physicians should learn to recognize and treat these common familial syndromes before the onset of CHD by evaluating family history and all three standard blood lipid determinations. Failure to recognize and treat them leaves affected family members at high risk of premature CHD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310276

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

1.  Evidence of linkage of HDL level variation to APOC3 in two samples with different ascertainment.

Authors:  France Gagnon; Gail P Jarvik; Arno G Motulsky; Samir S Deeb; John D Brunzell; Ellen M Wijsman
Journal:  Hum Genet       Date:  2003-08-29       Impact factor: 4.132

Review 2.  Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment.

Authors:  A N Nafziger
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

3.  Evidence of linkage of familial hypoalphalipoproteinemia to a novel locus on chromosome 11q23.

Authors:  E N Kort; D G Ballinger; W Ding; S C Hunt; B R Bowen; V Abkevich; K Bulka; B Campbell; C Capener; A Gutin; K Harshman; M McDermott; T Thorne; H Wang; B Wardell; J Wong; P N Hopkins; M Skolnick; M Samuels
Journal:  Am J Hum Genet       Date:  2000-04-17       Impact factor: 11.025

Review 4.  Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

Authors:  H S Malhotra; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Coronary risk factors and metabolic disorders in first-degree relatives of normocholesterolaemic patients with premature atherosclerosis.

Authors:  C A Geluk; C J M Halkes; P P Th De Jaegere; H W M Plokker; M Castro Cabezas
Journal:  Neth Heart J       Date:  2006-04       Impact factor: 2.380

6.  Genetic determination of high-density lipoprotein-cholesterol and apolipoprotein A-1 plasma levels in a family study of cardiac catheterization patients.

Authors:  V L Prenger; T H Beaty; P O Kwiterovich
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

7.  LIPITENSION: Interplay between dyslipidemia and hypertension.

Authors:  Jamshed J Dalal; T N C Padmanabhan; Piyush Jain; Shiva Patil; Hardik Vasnawala; Ashish Gulati
Journal:  Indian J Endocrinol Metab       Date:  2012-03

8.  Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated.

Authors:  Trond P Leren; Knut Erik Berge
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  The atherogenic and metabolic impact of non-HDL cholesterol versus other lipid sub-components among non-diabetic and diabetic Saudis.

Authors:  Nasser M Al-Daghri; Omar S Al-Attas; Khalid Al-Rubeaan
Journal:  Lipids Health Dis       Date:  2007-04-04       Impact factor: 3.876

10.  Serum Triglyceride Lowering Effect of Cilnidipine in Patients With Essential Hypertension.

Authors:  Prakash Kumar; Arijit Das; Satish Chandra; Manju Gari; U S P Keshri; Kusum Kumari
Journal:  Cardiol Res       Date:  2016-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.